Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude Tendril SDX

This article was originally published in The Gray Sheet

Executive Summary

Steroid-eluting active fixation pacing lead gains FDA market go-ahead March 20. With a 6.2 Fr diameter, the lead will permit a less traumatic insertion procedure with the use of a 7 Fr. introducer sheath and allow for optimal placement with an "electrically active collar," which allows the physician to map the inside of the heart prior to placement, St. Jude says. Separately, the St. Paul, Minnesota firm announced March 21 receipt of a CE mark for its Photon DR dual-chamber implantable cardioverter defibrillator and completion of patient enrollment for U.S. clinical studies. The 12.7 mm wide, 46 cc device is "the world's thinnest dual-chamber ICD," St. Jude claims. A premarket approval application submission is anticipated in "mid-2000," St. Jude says. The European launch is slated for the second quarter

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel